Pneumococcal Vaccine Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Pneumococcal Vaccines Market Report is Segmented by Vaccine Type (Conjugate Vaccine and Polysaccharide Vaccine), Product Type (Prevnar 13, Synflorix, and Pneumovax23), Distribution Channel (Distribution Partner Companies, Non-Governmental Organizations, and Government Authorities), and Geography (North America, Europe, Asia-Pacific, The Middle East and Africa, and South America). The Report Offers the Value (USD) for all the Above Segments.

Pneumococcal Vaccine Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Pneumococcal Vaccines Market Size

Pneumococcal Vaccines Market Summary
Study Period 2019 - 2030
Market Size (2025) USD 9.23 Billion
Market Size (2030) USD 11.68 Billion
CAGR (2025 - 2030) 4.83 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration High

Major Players

Pneumococcal Vaccines Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Pneumococcal Vaccines Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Pneumococcal Vaccines Market Analysis

The Pneumococcal Vaccines Market size is estimated at USD 9.23 billion in 2025, and is expected to reach USD 11.68 billion by 2030, at a CAGR of 4.83% during the forecast period (2025-2030).

The pneumococcal vaccines industry is experiencing significant transformation driven by technological advancements in vaccine development and production methodologies. Research institutions and pharmaceutical companies are increasingly focusing on innovative approaches to vaccine development, as exemplified by the Karolinska Institute's breakthrough in 2023 with their new vaccine candidate comprising nano-sized membrane vesicles. The integration of advanced technologies has enabled more efficient production processes and improved vaccine efficacy, leading to better patient outcomes. This technological evolution has also facilitated the development of more sophisticated vaccine delivery systems and storage solutions, addressing historical challenges in vaccine distribution and accessibility.


The industry landscape is witnessing a surge in research collaborations and strategic partnerships among key stakeholders. In June 2023, SK Bioscience demonstrated this trend by presenting positive results from Phase II clinical trials of their 21-valent pneumococcal conjugate vaccine candidate, GBP410, developed in collaboration with Sanofi. According to UNICEF's November 2023 data, approximately 2,000 children globally are affected by pneumonia daily, highlighting the critical need for such collaborative efforts in vaccine development. These partnerships are not only accelerating the pace of innovation but also enabling more comprehensive approaches to addressing global immunization challenges.


The pneumonia vaccine market is characterized by an increasing focus on vaccine accessibility and affordability, particularly in developing regions. Major manufacturers are implementing tiered pricing strategies and forming partnerships with international organizations to enhance vaccine distribution. For instance, in 2022, GlaxoSmithKline supplied approximately 40 million doses of the pneumococcal vaccine Synflorix at affordable prices to support eight low-income countries. This trend reflects a broader industry shift towards more equitable vaccine distribution and highlights the growing importance of corporate social responsibility in the pharmaceutical sector.


Regional disease surveillance and monitoring systems are becoming increasingly sophisticated, enabling better tracking and response to pneumococcal infections. In Australia, for example, Queensland reported 267 pneumococcal cases in 2023, compared to an average of 206 cases from 2018-2022, while New South Wales recorded over 450 cases from January to August 2023. This enhanced surveillance infrastructure is facilitating more targeted vaccination programs and helping healthcare systems better anticipate and respond to disease outbreaks. The improvement in monitoring capabilities is also contributing to more effective vaccine development strategies and implementation of immunization programs.

Segment Analysis: By Vaccine Type

Pneumococcal Conjugate Vaccine (PCV) Segment in Pneumococcal Vaccines Market

The Pneumococcal Conjugate Vaccine (PCV) segment continues to dominate the global pneumococcal vaccines market, commanding approximately 73% of the market share in 2024. This segment's prominence is primarily attributed to the widespread adoption of PCV in government immunization programs worldwide and its proven efficacy in preventing pneumococcal diseases. The segment's strong performance is further bolstered by the introduction of advanced PCVs that offer protection against multiple serotypes, such as the 20-valent and 15-valent vaccines. Additionally, the segment is experiencing the fastest growth trajectory with a projected growth rate of around 10% from 2024 to 2029, driven by increasing government awareness programs, rising prevalence of pneumococcal infections, and continuous technological advancements in vaccine development. The expansion of vaccination programs in developing countries and the introduction of novel PCVs by major pharmaceutical companies have also contributed significantly to this segment's market leadership. The price of PCV vaccines remains a critical factor in its widespread adoption, ensuring accessibility across various demographics.

Market Analysis of Pneumococcal Vaccines Market: Chart for By Vaccine Type

Pneumococcal Polysaccharide Vaccine (PPSV) Segment in Pneumococcal Vaccines Market

The Pneumococcal Polysaccharide Vaccine (PPSV) segment represents a crucial component of the pneumococcal vaccines market, particularly in adult vaccination programs. This segment serves a distinct market need by providing protection against 23 different serotypes of Streptococcus pneumoniae, making it especially valuable for adults aged 65 and older and individuals with certain medical conditions. The PPSV segment's importance is underscored by its complementary role to PCVs in comprehensive pneumococcal disease prevention strategies, particularly in high-risk populations. Healthcare providers often recommend PPSV as a follow-up to PCV vaccination in specific patient groups, highlighting its essential role in the overall vaccination landscape. The segment's market presence is supported by established vaccination guidelines from major health organizations and its proven track record in preventing invasive pneumococcal diseases in adult populations.

Segment Analysis: By Product Type

Prevnar 13 Segment in Pneumococcal Vaccines Market

Prevnar 13 continues to dominate the global pneumococcal vaccines market, commanding approximately 87% market share in 2024. This significant market position can be attributed to the vaccine's proven efficacy in providing immunity against 13 wide serotypes of Streptococcus pneumoniae bacteria. The segment's dominance is further strengthened by its widespread adoption in national immunization programs across multiple countries and its approval for use across different age groups, from infants to adults. The vaccine's long-lasting immunity against targeted strains and its contribution to reducing antibiotic resistance have made it a preferred choice among healthcare providers. Additionally, its cost-effectiveness in preventing hospitalizations and long-term healthcare expenses associated with pneumococcal infections has solidified its position as the market leader. The ongoing comparison of Vaxneuvance versus Prevnar highlights the competitive landscape in pneumonia vaccine brands.

Synflorix Segment in Pneumococcal Vaccines Market

The Synflorix segment demonstrates notable market dynamics despite facing competitive pressures. The vaccine utilizes advanced conjugate technology, where the antigen is linked to a carrier protein, enhancing the body's immune response particularly in infants and young children. Looking ahead to 2024-2029, the segment is expected to maintain its presence in the market through strategic initiatives and continued inclusion in national immunization programs. The vaccine's safety profile, proven efficacy, and well-documented clinical outcomes continue to support its adoption in various markets. Furthermore, its role in preventing multiple strains of pneumococcal infections and its established position in pediatric vaccination programs contribute to its sustained market presence.

Remaining Segments in Product Type

The Other Product Types segment encompasses several important vaccines including Prevnar 20, Pneumovax 23, Vaxneuvance, Sinovac PPV23, and PNEUMOSIL. These products play a crucial role in providing diverse options for pneumococcal disease prevention across different patient populations. Each product brings unique advantages, whether through broader serotype coverage, specific age group targeting, or cost-effectiveness for developing markets. The segment's diversity allows healthcare providers to select the most appropriate vaccine based on patient-specific factors, regional disease patterns, and economic considerations. The continued development and introduction of new vaccines in this segment demonstrate the industry's commitment to addressing evolving healthcare needs and expanding access to pneumococcal vaccination globally. The brand name of PCV 20 is particularly noteworthy for its expanded serotype coverage.

Segment Analysis: By Distribution Channel

Non-Governmental Organizations Segment in Pneumococcal Vaccines Market

Non-governmental organizations (NGOs) represent the dominant force in the pneumococcal vaccines market, commanding approximately 69% market share in 2024. These organizations play a pivotal role in vaccine distribution and accessibility, particularly in low- and middle-income countries where healthcare resources may be limited. NGOs like UNICEF and GAVI have established robust networks and supply agreements with major vaccine manufacturers to ensure affordable access to pneumococcal vaccines. For instance, UNICEF's partnership with the Serum Institute of India has made pneumococcal conjugate vaccines available at significantly reduced prices, enabling broader vaccination coverage in developing nations. The segment's growth is further propelled by increasing awareness campaigns, immunization programs, and collaborative efforts with governments and international organizations to reduce the global burden of pneumococcal diseases. The segment is expected to maintain its market leadership position through 2029, driven by continued focus on expanding vaccination coverage in underserved regions and strengthening healthcare infrastructure in developing countries.

Government Authorities Segment in Pneumococcal Vaccines Market

Government authorities represent a crucial distribution channel in the pneumococcal vaccines market, playing a vital role in implementing national immunization programs and ensuring vaccine accessibility. These authorities are responsible for vaccine procurement, distribution planning, and coordination with healthcare facilities to maintain consistent vaccine supply chains. Through various public health initiatives and vaccination programs, government authorities work to increase immunization rates and reduce the burden of pneumococcal diseases within their jurisdictions. The segment's growth is supported by increasing government investments in healthcare infrastructure, rising awareness about the importance of vaccination, and strengthening of national immunization programs. Additionally, government authorities collaborate with international health organizations and vaccine manufacturers to ensure adequate vaccine supplies and implement effective vaccination strategies, particularly in regions with high disease burden.

Remaining Segments in Distribution Channel

Distribution partner companies form another significant channel in the pneumococcal vaccines market, comprising authorized distributors and healthcare supply chain partners. These companies play a crucial role in maintaining the cold chain requirements and ensuring timely delivery of vaccines from manufacturers to healthcare facilities. They work closely with both pharmaceutical companies and healthcare providers to maintain product integrity throughout the distribution process. Distribution partners also provide valuable market insights and help manufacturers optimize their supply chain strategies. Their importance is particularly evident in regions with complex geographical terrains or limited healthcare infrastructure, where specialized distribution expertise is essential for maintaining vaccine efficacy and accessibility.

Pneumococcal Vaccines Market Geography Segment Analysis

Pneumococcal Vaccines Market in North America

North America represents a dominant force in the global pneumococcal vaccines market, driven by its advanced healthcare infrastructure, high awareness levels, and strong presence of key market players. The region benefits from comprehensive immunization programs, favorable reimbursement policies, and strategic government initiatives promoting vaccination coverage. The United States, Canada, and Mexico collectively contribute to the region's market leadership, with each country maintaining distinct healthcare policies and vaccination schedules tailored to their population needs.

Market Analysis of Pneumococcal Vaccines Market: Forecasted Growth Rate by Region

Pneumococcal Vaccines Market in the United States

The United States leads the North American market with approximately 90% regional market share, attributed to its robust healthcare system and extensive immunization programs. The country's market dominance is supported by the presence of major vaccine manufacturers, comprehensive CDC recommendations for pneumococcal vaccines, and high healthcare spending. The U.S. healthcare system's focus on preventive care, coupled with strong insurance coverage for vaccines, has facilitated widespread access to pneumococcal vaccines. The presence of a large elderly population and increasing awareness about the importance of vaccination among adults has further strengthened the market position.

Pneumococcal Vaccines Market in Mexico

Mexico emerges as the fastest-growing market in North America, with a projected growth rate of approximately 12% during 2024-2029. The country's market expansion is driven by increasing government initiatives to improve vaccination coverage, growing awareness about pneumococcal diseases, and rising healthcare expenditure. Mexico's healthcare system has been implementing comprehensive immunization programs, particularly focusing on pediatric vaccination. The country's high fertility rate compared to its North American counterparts and growing focus on preventive healthcare measures have created favorable conditions for market growth.

Pneumococcal Vaccines Market in Europe

Europe maintains a significant position in the global pneumococcal vaccines market, characterized by its well-established healthcare infrastructure and strong focus on preventive healthcare measures. The region's market is shaped by coordinated vaccination programs across different countries, with Germany, the United Kingdom, France, Italy, and Spain leading the way. The European market benefits from strong healthcare policies, government support for vaccination programs, and increasing awareness about pneumococcal diseases among the population.

Pneumococcal Vaccines Market in Germany

Germany stands as the largest market for pneumococcal vaccines in Europe, holding approximately 26% of the regional market share. The country's market leadership is supported by its robust healthcare system, comprehensive vaccination programs, and strong research and development infrastructure. The Germany pneumococcal vaccines market position is further strengthened by its aging population, high healthcare spending, and the presence of numerous scientific research institutes and biotechnology companies focused on vaccine development.

Pneumococcal Vaccines Market in France

France demonstrates the highest growth potential in the European region, with its strategic healthcare initiatives and expanding vaccination programs. The country's healthcare system has been actively promoting pneumococcal vaccination, particularly focusing on high-risk populations. France's market growth is supported by its strong pharmaceutical industry presence, increasing healthcare expenditure, and government initiatives to improve vaccination coverage across all age groups.

Pneumococcal Vaccines Market in Asia-Pacific

The Asia-Pacific region represents a rapidly evolving market for pneumococcal vaccines, characterized by its large population base, increasing healthcare awareness, and improving healthcare infrastructure. The region encompasses diverse markets including China, Japan, India, Australia, and South Korea, each with unique healthcare systems and vaccination policies. The market dynamics are influenced by government initiatives, rising healthcare expenditure, and growing awareness about preventive healthcare measures.

Pneumococcal Vaccines Market in China

China dominates the Asia-Pacific pneumococcal vaccines market, leveraging its vast population base and expanding healthcare infrastructure. The country's market leadership is driven by increasing government focus on immunization programs, growing healthcare expenditure, and rising awareness about pneumococcal diseases. The Chinese market benefits from ongoing healthcare reforms, improving access to vaccination services, and the presence of domestic vaccine manufacturers.

Pneumococcal Vaccines Market in India

India emerges as the fastest-growing market in the Asia-Pacific region, driven by its large pediatric population and increasing government focus on immunization programs. The country's market growth is supported by improving healthcare infrastructure, rising awareness about preventive healthcare, and the presence of major vaccine manufacturers. India's commitment to reducing childhood mortality through vaccination programs and the development of affordable vaccines has created significant growth opportunities.

Pneumococcal Vaccines Market in the Middle East & Africa

The Middle East & Africa region presents unique opportunities in the pneumonia vaccine market, with varying healthcare infrastructure levels across different countries. The region's market is primarily driven by government initiatives to improve vaccination coverage, particularly in GCC countries and South Africa. The GCC region leads the market size, while South Africa shows promising growth potential, supported by improving healthcare infrastructure and increasing awareness about pneumococcal diseases. The region's market dynamics are influenced by international healthcare organizations' support and growing government focus on preventive healthcare measures.

Pneumococcal Vaccines Market in South America

South America demonstrates growing potential in the pneumococcal vaccines market, characterized by improving healthcare infrastructure and increasing government focus on immunization programs. The region's market is primarily driven by Brazil and Argentina, with Brazil leading in market size and showing strong growth potential. The market benefits from government-sponsored vaccination programs, increasing healthcare awareness, and improving access to healthcare services. The region's commitment to reducing the burden of pneumococcal diseases through comprehensive vaccination programs continues to drive market growth.

Pneumococcal Vaccines Industry Overview

Top Companies in Pneumococcal Vaccines Market

The pneumococcal vaccines market is dominated by established pharmaceutical giants, including GlaxoSmithKline PLC, Pfizer Inc., Merck & Co. Inc., Serum Institute of India, CSL Ltd, and Sanofi. These companies are heavily investing in research and development to expand their product portfolios through next-generation conjugate vaccines market targeting additional serotypes. Strategic collaborations with research institutions and biotechnology firms have become increasingly common to accelerate innovation and clinical development timelines. Companies are also focusing on geographical expansion through distribution partnerships and manufacturing facility investments, particularly in emerging markets. The competitive landscape is characterized by continuous efforts to improve vaccine efficacy, reduce production costs, and enhance cold chain management capabilities to ensure broader market access.

Consolidated Market with High Entry Barriers

The pneumococcal vaccine market exhibits a highly consolidated structure dominated by multinational pharmaceutical conglomerates with established manufacturing capabilities and extensive distribution networks. These major players have built significant competitive advantages through decades of research experience, patent portfolios, and strong relationships with healthcare providers and regulatory authorities. Market entry barriers are substantial due to high capital requirements, complex manufacturing processes, stringent regulatory requirements, and the need for extensive clinical trial data. The industry has witnessed strategic acquisitions aimed at expanding technological capabilities and geographic reach, with larger companies acquiring smaller biotech firms with promising vaccine candidates or novel delivery technologies.


Recent years have seen increased participation from emerging market players, particularly from India and China, who are developing cost-effective alternatives to existing vaccines. However, the market remains dominated by established players who continue to maintain their position through continuous innovation, strong brand recognition, and extensive distribution capabilities. The industry structure is further reinforced by long-term supply agreements with government agencies and international organizations, creating stable revenue streams for incumbent players.

Innovation and Access Drive Future Success

Success in the pneumococcal vaccines market increasingly depends on companies' ability to develop next-generation vaccines with broader serotype coverage while maintaining competitive pricing. Market leaders must focus on technological innovation, manufacturing efficiency, and strategic partnerships to maintain their competitive position. Companies need to invest in advanced production technologies to reduce costs and improve scalability while maintaining product quality. Building strong relationships with healthcare providers, government agencies, and international organizations remains crucial for market success, as these stakeholders significantly influence vaccine adoption and distribution.


For new entrants and smaller players, success lies in developing differentiated products that address unmet needs or offer significant advantages over existing vaccines. This includes focusing on improved stability, easier administration, or better coverage of region-specific serotypes. Companies must navigate complex regulatory requirements while building robust supply chain capabilities to ensure reliable vaccine delivery. The increasing focus on vaccination programs in developing countries presents opportunities for companies that can offer cost-effective solutions while maintaining quality standards. Future success will also depend on companies' ability to adapt to evolving healthcare policies and potential regulatory changes affecting vaccine development and distribution.

Pneumococcal Vaccines Market Leaders

  1. Pfizer Inc.

  2. CSL Ltd.

  3. Serum Institute of India Pvt. Ltd.

  4. GSK plc

  5. Merck KGaA

  6. *Disclaimer: Major Players sorted in no particular order
Pneumococcal Vaccines Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Pneumococcal Vaccines Market News

  • April 2024: Merck presented the results of the phase 3 clinical trial STRIDE-10 for an investigational 21-valent pneumococcal conjugate vaccine developed for adults.
  • March 2024: Vaxcyte completed enrollment for the phase-2 clinical trial to evaluate the 24-valent pneumococcal conjugate vaccine (PCV) candidate VAX-24 to eradicate invasive pneumococcal disease (IPD) in children.

Pneumococcal Vaccine Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Government Awareness Programs Regarding Pneumonia Immunization
    • 4.2.2 Rising Prevalence Of Pneumonia
    • 4.2.3 Introduction of Novel Pneumococcal Vaccines
  • 4.3 Market Restraints
    • 4.3.1 Long Duration for the Production
    • 4.3.2 High Cost of Production
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Buyers/Consumers
    • 4.4.2 Bargaining Power of Suppliers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD)

  • 5.1 By Vaccine Type
    • 5.1.1 Pneumococcal conjugate vaccine
    • 5.1.2 Pneumococcal polysaccharide vaccine
  • 5.2 By Product Type
    • 5.2.1 Prevnar 13
    • 5.2.2 Synflorix
    • 5.2.3 Pneumovax23
  • 5.3 By Distribution Channel
    • 5.3.1 Distribution partner companies
    • 5.3.2 Non-governmental Organizations
    • 5.3.3 Government Authorities
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 GSK PLC
    • 6.1.2 Pfizer Inc.
    • 6.1.3 Merck KGaA
    • 6.1.4 Serum Institute of India Pvt. Ltd
    • 6.1.5 CSL Ltd
    • 6.1.6 Sanofi S.A
    • 6.1.7 Walvax Biotechnology Co. Ltd
    • 6.1.8 Beijing Minhai Biotechnology Co. Ltd
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Pneumococcal Vaccines Industry Segmentation

Pneumonia is a type of acute respiratory illness that affects the lungs, in which the alveoli are filled with pus and fluid, making breathing painful and limiting oxygen intake. 

The pneumococcal vaccine market is segmented by vaccine type, product type, distribution channel, and geography. By vaccine type, the market is segmented into conjugate vaccines and polysaccharide vaccines. By product type, the market is segmented into Prevnar 13, SynflorIX, and Pneumovax2. By distribution channel, the market is segmented into distribution partner companies, non-governmental organizations, and government authorities. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. For each segment, the market size is provided in terms of value (USD).

By Vaccine Type Pneumococcal conjugate vaccine
Pneumococcal polysaccharide vaccine
By Product Type Prevnar 13
Synflorix
Pneumovax23
By Distribution Channel Distribution partner companies
Non-governmental Organizations
Government Authorities
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Pneumococcal Vaccine Market Research FAQs

How big is the Pneumococcal Vaccines Market?

The Pneumococcal Vaccines Market size is expected to reach USD 9.23 billion in 2025 and grow at a CAGR of 4.83% to reach USD 11.68 billion by 2030.

What is the current Pneumococcal Vaccines Market size?

In 2025, the Pneumococcal Vaccines Market size is expected to reach USD 9.23 billion.

Who are the key players in Pneumococcal Vaccines Market?

Pfizer Inc., CSL Ltd., Serum Institute of India Pvt. Ltd., GSK plc and Merck KGaA are the major companies operating in the Pneumococcal Vaccines Market.

Which is the fastest growing region in Pneumococcal Vaccines Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Pneumococcal Vaccines Market?

In 2025, the North America accounts for the largest market share in Pneumococcal Vaccines Market.

What years does this Pneumococcal Vaccines Market cover, and what was the market size in 2024?

In 2024, the Pneumococcal Vaccines Market size was estimated at USD 8.78 billion. The report covers the Pneumococcal Vaccines Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Pneumococcal Vaccines Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Pneumococcal Vaccines Market Research

Mordor Intelligence provides a comprehensive analysis of the pneumococcal vaccines market, drawing on our extensive experience in healthcare industry research. Our detailed report covers the full range of conjugate vaccines and their applications. It includes the latest developments, such as the introduction of the new pneumonia vaccine 2023. The analysis encompasses major products like PCV variants and PPSV, with a special focus on emerging products such as Prevnar 20 and Vaxneuvance. We offer detailed insights into pneumococcal vaccine ages recommendations and examine the dynamics of the invasive pneumococcal disease market.

Our report provides stakeholders with valuable insights into pneumonia vaccine brands and pricing trends. It includes a detailed analysis of PCV vaccine price variations across different regions. The research covers key markets, including the Germany pneumococcal vaccines market, as well as emerging markets like Prevnar 20 in India. Stakeholders benefit from our thorough coverage of streptococcus pneumoniae vaccine developments and Synflorix vaccine for adults applications. The report, available in an easy-to-download PDF format, includes a detailed analysis of the pneumococcal vaccine market size and future growth projections, making it an essential tool for industry decision-makers.